AI Tokens
Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Return on Capital (ROC)

Microsoft Excel

Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.


Return on Invested Capital (ROIC)

Boston Scientific Corp., ROIC calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1 1,099 1,270 153 829 1,711
Invested capital2 22,868 22,038 21,053 20,389 16,047
Performance Ratio
ROIC3 4.81% 5.76% 0.73% 4.06% 10.66%
Benchmarks
ROIC, Competitors4
Abbott Laboratories 10.96% 11.30% — — —
Elevance Health Inc. 10.24% 11.26% — — —
Intuitive Surgical Inc. 22.01% 37.63% — — —
Medtronic PLC 7.02% 5.59% — — —
UnitedHealth Group Inc. 13.68% 13.51% — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 NOPAT. See details »

2 Invested capital. See details »

3 2022 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × 1,099 ÷ 22,868 = 4.81%

4 Click competitor name to see calculations.


The financial performance regarding capital efficiency from 2018 to 2022 is characterized by significant volatility in operating profitability contrasted against a steady increase in the invested capital base.

Net Operating Profit After Taxes (NOPAT)
A substantial decline in NOPAT is observed between 2018 and 2020, falling from $1,711 million to a low of $153 million. Although a significant recovery occurred in 2021 with profit rising to $1,270 million, the figure retreated to $1,099 million in 2022, indicating that operating profitability has remained below the levels observed in 2018.
Invested Capital
The invested capital base demonstrates a consistent upward trajectory throughout the analyzed period. Starting at $16,047 million in 2018, the capital expanded annually to reach $22,868 million by December 31, 2022, representing a sustained increase in the resources deployed into the business.
Return on Invested Capital (ROIC)
ROIC experienced a severe contraction, dropping from 10.66% in 2018 to a nadir of 0.73% in 2020. This decline was the result of sharply decreasing operating profits occurring alongside an expanding capital base. While a recovery to 5.76% was achieved in 2021, the ratio moderated to 4.81% in 2022. The overall trend reflects a diminished rate of return on invested capital relative to the 2018 baseline.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Decomposition of ROIC

Boston Scientific Corp., decomposition of ROIC

Microsoft Excel
ROIC = OPM1 × TO2 × 1 – CTR3
Dec 31, 2022 4.81% = 12.99% × 0.56 × 66.58%
Dec 31, 2021 5.76% = 12.71% × 0.54 × 83.43%
Dec 31, 2020 0.73% = 3.21% × 0.47 × 48.11%
Dec 31, 2019 4.06% = 11.20% × 0.53 × 68.73%
Dec 31, 2018 10.66% = 17.07% × 0.61 × 101.99%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Operating profit margin (OPM). See calculations »

2 Turnover of capital (TO). See calculations »

3 Effective cash tax rate (CTR). See calculations »


The return on invested capital (ROIC) exhibited significant volatility between 2018 and 2022, characterized by a sharp contraction followed by a partial recovery. A peak ROIC of 10.66% in 2018 declined precipitously to a low of 0.73% by 2020. While a recovery occurred in 2021, reaching 5.76%, the metric slightly retreated to 4.81% by the end of 2022, indicating that the organization has not yet returned to its 2018 efficiency levels.

Operating Profit Margin (OPM)
The operating profit margin acted as the primary driver of ROIC volatility. A severe downward trend was observed from 2018 to 2020, where the margin collapsed from 17.07% to 3.21%. This contraction suggests a period of significant operational pressure or increased costs. However, a robust recovery followed, with the margin climbing back to 12.71% in 2021 and stabilizing at 12.99% in 2022, signaling a restoration of operational profitability.
Turnover of Capital (TO)
Capital turnover showed a consistent pattern of decline followed by a gradual recovery. The ratio decreased from 0.61 in 2018 to a trough of 0.47 in 2020, reflecting a reduction in the efficiency of capital deployment to generate revenue. From 2021 onward, a slow upward trajectory is noted, with the ratio reaching 0.56 by 2022, though it remains below the 2018 baseline.
Effective Cash Tax Rate Multiplier (1 – CTR)
The tax multiplier exhibited extreme fluctuations throughout the period. A value exceeding 100% in 2018 (101.99%) suggests the presence of tax credits or negative tax expenses that artificially boosted the ROIC. This figure dropped significantly to 48.11% in 2020, coinciding with the lowest ROIC. A spike to 83.43% in 2021 supported the recovery of ROIC, while a subsequent decline to 66.58% in 2022 contributed to the slight erosion of the final return despite stable operating margins.

The decomposition analysis reveals that the precipitous drop in ROIC through 2020 was a systemic failure across all three components: profitability, asset efficiency, and tax positioning. The subsequent recovery was primarily driven by the rebound in operating profit margins. The 2022 decline in ROIC, despite improvements in OPM and capital turnover, is attributable to the contraction in the tax multiplier, highlighting the sensitivity of the final return to effective cash tax variations.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Operating Profit Margin (OPM)

Boston Scientific Corp., OPM calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1 1,099 1,270 153 829 1,711
Add: Cash operating taxes2 552 252 165 377 (33)
Net operating profit before taxes (NOPBT) 1,650 1,522 318 1,206 1,677
 
Net sales 12,682 11,888 9,913 10,735 9,823
Add: Increase (decrease) in deferred revenue 25 89 (5) 27 —
Adjusted net sales 12,707 11,977 9,908 10,762 9,823
Profitability Ratio
OPM3 12.99% 12.71% 3.21% 11.20% 17.07%
Benchmarks
OPM, Competitors4
Abbott Laboratories 20.24% 20.37% — — —
Elevance Health Inc. 5.64% 6.58% — — —
Intuitive Surgical Inc. 26.19% 33.56% — — —
Medtronic PLC 19.15% 16.48% — — —
UnitedHealth Group Inc. 9.13% 8.33% — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2022 Calculation
OPM = 100 × NOPBT ÷ Adjusted net sales
= 100 × 1,650 ÷ 12,707 = 12.99%

4 Click competitor name to see calculations.


The operating performance from 2018 to 2022 is characterized by significant volatility, marked by a severe contraction in 2020 followed by a robust recovery. While top-line revenue demonstrated a general upward trajectory over the five-year period, the efficiency of converting sales into operating profit experienced a notable disruption.

Net Operating Profit Before Taxes (NOPBT)
NOPBT decreased from $1,677 million in 2018 to a trough of $318 million in 2020, representing a substantial decline in operational earnings. A strong rebound occurred in 2021 and 2022, with the 2022 figure reaching $1,650 million, effectively restoring the absolute dollar value of operating profit to levels nearly equivalent to those seen in 2018.
Adjusted Net Sales
Revenue trends indicate overall growth, increasing from $9,823 million in 2018 to $12,707 million in 2022. Aside from a temporary dip in 2020 to $9,908 million, adjusted net sales grew consistently, suggesting a resilient market position and successful revenue expansion despite the volatility in profit margins.
Operating Profit Margin (OPM)
The OPM exhibited a sharp decline from 17.07% in 2018 to a low of 3.21% in 2020. Although the margin recovered to 12.99% by the end of 2022, it remains below the 2018 baseline. This indicates that while absolute profitability recovered, the company's operating cost structure scaled more aggressively relative to sales than it had in 2018.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Turnover of Capital (TO)

Boston Scientific Corp., TO calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net sales 12,682 11,888 9,913 10,735 9,823
Add: Increase (decrease) in deferred revenue 25 89 (5) 27 —
Adjusted net sales 12,707 11,977 9,908 10,762 9,823
 
Invested capital1 22,868 22,038 21,053 20,389 16,047
Efficiency Ratio
TO2 0.56 0.54 0.47 0.53 0.61
Benchmarks
TO, Competitors3
Abbott Laboratories 0.71 0.69 — — —
Elevance Health Inc. 2.33 2.14 — — —
Intuitive Surgical Inc. 1.16 1.27 — — —
Medtronic PLC 0.46 0.42 — — —
UnitedHealth Group Inc. 1.95 2.04 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Invested capital. See details »

2 2022 Calculation
TO = Adjusted net sales ÷ Invested capital
= 12,707 ÷ 22,868 = 0.56

3 Click competitor name to see calculations.


The financial performance from 2018 to 2022 is characterized by a period of significant capital expansion and fluctuating revenue generation, which directly influenced the efficiency of capital utilization.

Adjusted Net Sales Evolution
Adjusted net sales demonstrated an overall upward trend, increasing from 9,823 million US$ in 2018 to 12,707 million US$ in 2022. A temporary contraction occurred in 2020, with sales decreasing to 9,908 million US$, before a strong recovery was observed in 2021 and 2022.
Invested Capital Expansion
Invested capital grew consistently throughout the five-year period, rising from 16,047 million US$ in 2018 to 22,868 million US$ in 2022. The most substantial increase took place between 2018 and 2019, reflecting a significant expansion of the company's asset base.
Capital Turnover Dynamics
The turnover of capital ratio followed a U-shaped trajectory. An initial decline is observed from 0.61 in 2018 to a low of 0.47 in 2020, indicating that the growth in invested capital outpaced revenue growth during this interval. A subsequent recovery phase occurred between 2021 and 2022, with the ratio improving to 0.56. While the efficiency of capital utilization is trending upward, it remains below the 2018 level.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Effective Cash Tax Rate (CTR)

Boston Scientific Corp., CTR calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1 1,099 1,270 153 829 1,711
Add: Cash operating taxes2 552 252 165 377 (33)
Net operating profit before taxes (NOPBT) 1,650 1,522 318 1,206 1,677
Tax Rate
CTR3 33.42% 16.57% 51.89% 31.27% -1.99%
Benchmarks
CTR, Competitors4
Abbott Laboratories 23.97% 20.05% — — —
Elevance Health Inc. 22.01% 20.22% — — —
Intuitive Surgical Inc. 27.40% 11.76% — — —
Medtronic PLC 19.53% 18.59% — — —
UnitedHealth Group Inc. 23.25% 20.32% — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2022 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 552 ÷ 1,650 = 33.42%

4 Click competitor name to see calculations.


The financial performance between 2018 and 2022 is characterized by significant volatility in both operating profitability and cash tax obligations, resulting in an unstable effective cash tax rate over the five-year period.

Net Operating Profit Before Taxes (NOPBT)
Operating profitability experienced a severe contraction, falling from 1,677 million in 2018 to a period low of 318 million in 2020. A robust recovery was observed thereafter, with NOPBT climbing to 1,522 million in 2021 and reaching 1,650 million by 2022, effectively restoring profitability to near 2018 levels.
Cash Operating Taxes
Cash outflows for taxes showed an inconsistent trend, beginning with a negative value of -33 million in 2018, which indicates a tax benefit or refund. Payments rose sharply in 2019, dipped in 2020, and subsequently increased to a peak of 552 million in 2022. The overall trajectory indicates a substantial increase in absolute cash tax payments over the analyzed timeframe.
Effective Cash Tax Rate (CTR)
The CTR demonstrated extreme fluctuations, moving from -1.99% in 2018 to a peak of 51.89% in 2020. The 2020 surge is particularly significant as it represents an inverse correlation between operating profit and the tax rate; the rate peaked exactly when NOPBT was at its lowest. This indicates that cash tax burdens remained disproportionately high relative to earnings during that year. The rate normalized to 16.57% in 2021 before settling at 33.42% in 2022, suggesting a return to a more standard tax profile.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?